PersonFounderScientist
John Mulligan
John Mulligan is the founder and CEO of Bonum Therapeutics, a Seattle biotech building antibody-regulated biologics that switch on only at their target. A serial entrepreneur with roughly 30 years across drug discovery and company formation, he has founded four companies in fields he often entered as a novice - including Good Therapeutics, whose PD-1-regulated IL-2 program Roche acquired in 2022 for $250M upfront. Bonum spun out of that deal with $93M in Series A funding to apply the same conditional-activation science across oncology, autoimmunity, metabolic disease, and pain. Mulligan holds a BS in biology from MIT and a PhD from Stanford, and was named a Top Industry Leader by the PharmaVoice 100 in 2023.
john mulliganbonum therapeuticsgood therapeuticsblue heron biotechglycostasisseattle biotech
